Enhanced Clostridioides difficile Infection Prevention With a Pharmacy-Controlled Policy That Adds a 3-Strain Lactobacillus Probiotic Concomitantly to Antibiotic Therapy

Pierre-Jean Maziade; Noam Ship; Jason C Sniffen; Ellie J C Goldstein

doi:10.1093/cid/ciab414

Enhanced Clostridioides difficile Infection Prevention With a Pharmacy-Controlled Policy That Adds a 3-Strain Lactobacillus Probiotic Concomitantly to Antibiotic Therapy

Clin Infect Dis. 2021 Oct 20;73(8):1524-1527. doi: 10.1093/cid/ciab414.

Authors

Pierre-Jean Maziade¹, Noam Ship², Jason C Sniffen³, Ellie J C Goldstein⁴

Affiliations

¹ Microbiology and Infectious Diseases, Centre Intégré de Santé et de Services Sociaux de Lanaudière, Terrebonne, Quebec, Canada.
² Research and Development, Bio-K Plus International, Laval, Quebec, Canada.
³ AdventHealth Orlando, Orlando, Florida, USA.
⁴ R. M. Alden Research Laboratory, Santa Monica, California, USA.

Abstract

When 70% of antibiotic users took a 3-strain Lactobacillus probiotic preparation the hospital-wide rate of healthcare-associated Clostridioides difficile infection improved significantly. The incidence of C. difficile infection for those taking the probiotic along with multiple antibiotics or a single high-risk antibiotic was decreased by at least half.

Keywords: Clostridium difficile infection; Lactobacillus; CL1285; Primary prevention; Probiotic.

MeSH terms

Anti-Bacterial Agents / therapeutic use
Clostridioides
Clostridioides difficile*
Clostridium Infections* / prevention & control
Diarrhea
Humans
Lactobacillus
Pharmacy*
Policy
Probiotics*

Substances

Anti-Bacterial Agents